INS and type 1 diabetes mellitus: By now, the mainstay therapy for T1D patients is exogenous insulin therapy, which is typically delivered via a subcutaneous insulin infusion or multiple daily injections (Katsarou et al., 2017; Beck et al., 2019; Warshauer et al., 2020).